Pfiz­er’s once-a-week he­mo­phil­ia an­ti­body re­duces bleed­ing in PhI­II study

Pfiz­er’s once-a-week an­ti­body treat­ment for he­mo­phil­ia A and B helped re­duce bleed­ing events in pa­tients com­pared to their usu­al treat­ment of blood clot­ting fac­tor in­fu­sions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER